Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
Validated PROMs can assist in providing high-quality care and improve a patient’s overall experience.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
Men with metastatic castration-resistant prostate cancer with predominantly bone metastases who receive more than 4 dose of radium-223 have significantly improved overall survival than those who receive 4 or fewer doses, a study found.
Phase 2 trial results suggests abiraterone used in combination in cabazitaxel in men with chemotherapy-naïve metastatic castration-resistant prostate cancer might prolong radiographic progression-free survival compared with abiraterone alone.
In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with utilization of newer oral androgen pathway inhibitors therapy without sipuleucel-T.